Tooba Rehman: Extending Impella 5.5 Support Beyond 14 Days in Cardiogenic Shock
Tooba Rehman, Medical Doctor, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Delighted to share my latest publication:
Impact of Impella 5.5 Duration Support and Clinical Outcomes in Cardiogenic Shock: A Systematic Review and Meta-Analysis
Cardiogenic shock remains one of the most challenging conditions we manage, and optimizing mechanical circulatory support strategies is critical.
In our latest meta-analysis (1,440 patients across 5 studies), we explored whether extending Impella 5.5 support beyond 14 days offers meaningful clinical benefits.
Grateful to my Amazing Team!”
Title: Impact of Impella 5.5 Duration Support and Clinical Outcomes in Cardiogenic Shock: Evidence from a Systematic Review and Meta-Analysis of Observational Studies
Authors: Mrunalini Dandamudi, Srinivas Vunnamb, Tooba Rehman, Muhammad Aqib Faizan, Miguel A Samaniego-Laguna, John Cedric Mojica, Juliana Giorgi
Read the Full Article on JHTL OPEN

Muhammad Aqib Faizan, Clinical Intern at District Headquarter Hospital, MTI, DIKhan, shared this post, adding:
“Significantly higher risk of implant-site hematoma and infection necessitates meticulous vascular management, infection-prevention strategies and close clinical surveillance.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed